drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
A half-life–extended ImmTAC (TCR-based bispecific biologic) comprising a soluble, high-affinity TCR that binds PRAME peptide presented by HLA-A*02:01 on tumor cells fused to an anti-CD3 effector to recruit and activate T cells, redirecting cytotoxic T cells to PRAME-positive cancer cells and inducing tumor cell lysis.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Bispecific Antibodies
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
A half-life–extended ImmTAC (TCR-based bispecific) that uses a soluble, high-affinity TCR to bind PRAME peptide presented by HLA-A*02:01 on tumor cells and an anti-CD3 effector to recruit and activate T cells, redirecting polyclonal T cells to PRAME-positive cells to form an immune synapse, trigger TCR–CD3 signaling and cytokine release, and induce tumor cell lysis (HLA-A*02:01-restricted).
drug_name
IMC-P115C
nct_id_drug_ref
NCT07156136